Skip to main content
Fiona Adams

Fiona Adams is the Managing Shareholder of the London office and the Co-Chair of the Global Corporate Practice. She primarily represents corporate clients, focusing her practice on mergers and acquisitions, and other transactional matters. Her work spans a range of industries, including pharmaceuticals, financial institutions, media and retail. Fiona has broad experience working on large, complex cross-border transactions.

Fiona continues to be highly recommended by both of the leading independent guides to the legal industry. According Chambers & Partners 2019, Fiona Adams "deploys a 'user friendly, commercial and down-to-earth' demeanor." The Legal 500 2020 edition advises "Fiona Adams is an outstanding M&A lawyer with great customer service."

Concentrations

  • Mergers and acquisitions
  • Corporate transactions
  • Joint ventures

Capabilities

Experience

  • Advised AstraZeneca AB on its agreement with Grünenthal to divest the European rights to Nexium for an upfront payment of $700 million with further sales-related and milestone payments of up to $90 million.
  • Advised AstraZeneca AB on its agreement with Grünenthal to divest the global rights to Vimovo in all markets excluding the United States and Japan for an upfront payment of $115 million and further payments up to another $17 million.
  • Advised AstraZeneca AB on its US$243 million divestment to Cheplapharm of the global rights (excluding China, Japan, USA and Mexico) for LOSEC (omeprazole) and associated brands.
  • Advised AstraZeneca AB on its US$236 million sale of Atacand to German pharma company Cheplapharm Arzneimittel. Atacand is a prescription medicine for the treatment of heart failure and hypertension.
  • Advised Rentokil Initial plc the world’s leading commercial pest control services provider on the worldwide acquisition of Cannon Hygiene business from OCS Group Limited.
  • Advised a US bridging group on the acquisition of a UK modular bridging business.
  • Advised AB Volvo in the sale of 75.1% of the issued shares in WirelessCar Sweden AB (an automotive telematics company) by Volvo Information Technology AB to Volkswagen Finance Luxemburg SA.
  • Advised AstraZeneca plc on its agreement with Grünenthal to divest rights to migraine treatment Zomig in all markets outside Japan.
  • Advised Rentokil Initial plc on its joint venture agreement with Haniel & Cie. Holding Company which created a leading provider of workwear and hygiene services in Europe with combined revenues of c. €1.1bn.
  • Advised AstraZeneca plc on the sale of its small molecule antibiotics business to Pfizer for US$725m.
  • Advised AstraZeneca plc on its agreement with China Medical System Holdings and its associated company Tibet Rhodiola Pharmaceutical Holdings Co., Ltd., to divest Imdur, a mature medicine for the prevention of angina in patients with heart disease for the global market for US$190m.
  • Advised AB Volvo on the sale of its external IT operation and the operation of its IT infrastructure to HCL Technologies for a capital gain corresponding to SEK900m.
  • Advised IHG in the £350 million sale of Intercontinental Park Lane hotel and management agreement back to IHG.
  • Advised AB Volvo on the sale of its North American construction equipment rental business to Platinum Equity for $1.1bn.
  • Advised Rentokil Initial plc on the sale of its Initial Facilities business to Interserve plc for £250m.
  • Advised AB Volvo on the sale of its Volvo Aero aircraft engines business to GKN (Holdings) plc for £700m.
  • Advised Nomura's brokerage services division, Instinet Incorporated, on the divestment of a majority stake in its MarketPrizm business to Colt Telecom.
  • Advised AstraZeneca plc on the sale of AstraTech business to Dentsply for $1.8bn.
  • Advised Rentokil Initial plc on its acquisition of Knightsbridge Guarding Holdings Limited and KGL Business Services Limited.
  • Advised Rentokil Initial plc on its acquisition of the pest, fire and water businesses from Connaught plc (in administration).
  • Advised Rentokil Initial plc on its acquisition of the building services and facilities management division of Managed Support Services plc.
  • Advised Smiths Group plc in relation to its joint venture with Analogic.
  • Advised Healthcor, 3i and senior management of ApaTech Limited in its US$330m sale to global health care company Baxter International Inc.
  • Partner, Mayer Brown, 2000-2009
  • Associate, Mayer Brown, 1991-2000
  • Foreign Associate, New York office of an international law firm, 1997
  • General Counsel, HMV Media Group plc, 2000

Recognition & Leadership

  • Listed, Best Lawyers in the United Kingdom, "Mergers and Acquisitions Law," 2015-2020 
  • Listed, IFLR 1000 United Kingdom
    • "Highly Regarded" M&A, 2019-2020
    • "Leading Lawyers" M&A, 2017-2018
  • Listed, Chambers Global, Corporate/ M&A (UK), 2014-2019
  • Listed, Chambers UK Guide, Corporate/M&A, 2012-2020
  • Listed, The Legal 500 United Kingdom, Corporate and Commercial – M&A: Upper Mid-Market and Premium Deals, 2012-2020

Credentials

Education
  • B.Sc., De Montfort University, 1989
Admissions
  • England and Wales